Personalized ctDNA Detection to Monitor Outcome and Predict Immunotherapy Benefit in Locally Advanced and Metastatic NSCLC

被引：0
|
作者：
Gao, G. [1 ]
Cheng, L. [2 ]
Zhao, C. [2 ]
Li, X. [2 ]
Yao, C. [3 ]
Li, F. [3 ]
You, D. [3 ]
Zhou, C. [1 ]
机构：
[1] Shanghai Pulm Hosp, Dept Med Oncol, Shanghai, Peoples R China
[2] Shanghai Pulm Hosp, Dept Lung Canc & Immunol, Shanghai, Peoples R China
[3] Shanghai OrigiMed Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
Immune checkpoint inhibitors; circulating tumor DNA; Response monitoring;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.01-03
引用
收藏
页码：S353 / S354
页数：2
相关论文
共 50 条
  • [1] Personalized circulating tumor DNA detection to monitor immunotherapy efficacy and predict outcome in locally advanced or metastatic non-small cell lung cancer
    Cheng, Lei
    Gao, Guanghui
    Zhao, Chao
    Wang, Haowei
    Yao, Chao
    Yu, Hanchuanzhi
    Yao, Jichen
    Li, Feng
    Guo, Lijie
    Jian, Qijie
    Chen, Xiaoxia
    Li, Xuefei
    Zhou, Caicun
    CANCER MEDICINE, 2023, 12 (13): : 14317 - 14326
  • [2] Residual ctDNA Detection Predicts Benefit From Definitive Chemoradiotherapy and Immune Checkpoint Inhibitors in Locally Advanced NSCLC
    Wang, Y.
    Yang, Y.
    Zhang, T.
    Wang, J.
    Wang, L.
    Bi, N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : S30 - S30
  • [3] The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial (SPRINT)
    Ohri, N.
    Jolly, S.
    Cooper, B. T.
    Kabarriti, R.
    Bodner, W. R., III
    Klein, J.
    Viswanathan, S.
    Kaufman, R.
    Shum, E.
    Sabari, J. K.
    Cheng, H.
    Gucalp, R.
    Castellucci, E.
    Qin, A.
    Gadgeel, S. M.
    Halmos, B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : S31 - S31
  • [4] Experts Discuss Personalized ctDNA Assays to Predict Immunotherapy Response
    Ansstas, George
    Badin, Firas B.
    ONCOLOGY-NEW YORK, 2021, 35 (09): : 592 - 593
  • [5] Use of Biosimulation to Predict Chemotherapy Benefit in Patients with Metastatic NSCLC Being Treated with Immunotherapy
    Klein, M.
    Watson, D.
    Kapoor, S.
    Nair, P. R.
    Rajagopalan, S.
    Glaser, M.
    Sharif, N.
    Stonebarger, M.
    Westanmo, A.
    Lala, D. A.
    Kumar, A.
    Chauhan, J.
    Ullal, Y. S.
    Kulkarni, S.
    Ghosh, A.
    Narvekar, Y.
    Patil, M.
    Castro, M.
    Macpherson, M.
    Wingrove, J.
    Patil, T.
    Ganti, A.
    Aggarwal, C.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S89 - S89
  • [6] Metastatic Lymph Nodes as High Immunogenicity Media for Perioperative Immunotherapy in Locally Advanced NSCLC
    Zhang, C.
    Liu, S.
    Su, J.
    Gao, X.
    Chang, L.
    Guan, Y.
    Tu, H.
    Yang, J.
    Zhang, X.
    Zhong, W.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S130 - S131
  • [7] Radiation Therapy and Immunotherapy in Locally Advanced NSCLC
    Lee, Percy
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (05) : 288 - 290
  • [8] PET in the management of locally advanced and metastatic NSCLC
    Grootjans, Willem
    de Geus-Oei, Lioe-Fee
    Troost, Esther G. C.
    Visser, Eric P.
    Oyen, Wim J. G.
    Bussink, Johan
    NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (07) : 395 - 407
  • [9] PET in the management of locally advanced and metastatic NSCLC
    Willem Grootjans
    Lioe-Fee de Geus-Oei
    Esther G. C. Troost
    Eric P. Visser
    Wim J. G. Oyen
    Johan Bussink
    Nature Reviews Clinical Oncology, 2015, 12 : 395 - 407
  • [10] Immunotherapy in the Frontline Management of Advanced and Metastatic NSCLC
    Segal, Eve M.
    AMERICAN JOURNAL OF MANAGED CARE, 2021, 27 (18): : S323 - S332
12345